235 related articles for article (PubMed ID: 31035004)
1. The S1P mimetic fingolimod phosphate regulates mitochondrial oxidative stress in neuronal cells.
Martín-Montañez E; Pavia J; Valverde N; Boraldi F; Lara E; Oliver B; Hurtado-Guerrero I; Fernandez O; Garcia-Fernandez M
Free Radic Biol Med; 2019 Jun; 137():116-130. PubMed ID: 31035004
[TBL] [Abstract][Full Text] [Related]
2. Neuronal Metabolism and Neuroprotection: Neuroprotective Effect of Fingolimod on Menadione-Induced Mitochondrial Damage.
Gil A; Martín-Montañez E; Valverde N; Lara E; Boraldi F; Claros S; Romero-Zerbo SY; Fernández O; Pavia J; Garcia-Fernandez M
Cells; 2020 Dec; 10(1):. PubMed ID: 33383658
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement.
Bordet R; Camu W; De Seze J; Laplaud DA; Ouallet JC; Thouvenot E
Rev Neurol (Paris); 2020; 176(1-2):100-112. PubMed ID: 31757428
[TBL] [Abstract][Full Text] [Related]
4. Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
Salas-Perdomo A; Miró-Mur F; Gallizioli M; Brait VH; Justicia C; Meissner A; Urra X; Chamorro A; Planas AM
Sci Rep; 2019 Jun; 9(1):8309. PubMed ID: 31165772
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.
Chun J; Kihara Y; Jonnalagadda D; Blaho VA
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():149-170. PubMed ID: 30625282
[TBL] [Abstract][Full Text] [Related]
6. Morpholino Analogues of Fingolimod as Novel and Selective S1P
Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
[TBL] [Abstract][Full Text] [Related]
7. Potential sphingosine-1-phosphate-related therapeutic targets in the treatment of cerebral ischemia reperfusion injury.
Han M; Sun T; Chen H; Han M; Wang D
Life Sci; 2020 May; 249():117542. PubMed ID: 32169519
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson's disease and in MPP+ -treated MN9D cells in vitro.
Sivasubramanian M; Kanagaraj N; Dheen ST; Tay SS
Neuroscience; 2015 Apr; 290():636-48. PubMed ID: 25637806
[TBL] [Abstract][Full Text] [Related]
9. Lessons from S1P receptor targeting in multiple sclerosis.
Colombo E; Farina C
Pharmacol Ther; 2022 Feb; 230():107971. PubMed ID: 34450231
[TBL] [Abstract][Full Text] [Related]
10. The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.
Leo A; Citraro R; Marra R; Palma E; Paola EDD; Constanti A; De Sarro G; Russo E
CNS Neurol Disord Drug Targets; 2017; 16(3):311-325. PubMed ID: 27823573
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.
Nystad AE; Lereim RR; Wergeland S; Oveland E; Myhr KM; Bø L; Torkildsen Ø
J Neuroimmunol; 2020 Feb; 339():577091. PubMed ID: 31739156
[TBL] [Abstract][Full Text] [Related]
12. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
[TBL] [Abstract][Full Text] [Related]
14. Hepatic insulin resistance induced by mitochondrial oxidative stress can be ameliorated by sphingosine 1-phosphate.
Fang H; Feng Q; Shi Y; Zhou J; Wang Q; Zhong L
Mol Cell Endocrinol; 2020 Feb; 501():110660. PubMed ID: 31759099
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and Optimization of
Gusman DH; Shoemake C
Yale J Biol Med; 2017 Mar; 90(1):15-23. PubMed ID: 28356890
[TBL] [Abstract][Full Text] [Related]
16. To fingolimod and beyond: The rich pipeline of drug candidates that target S1P signaling.
Chew WS; Wang W; Herr DR
Pharmacol Res; 2016 Nov; 113(Pt A):521-532. PubMed ID: 27663260
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling.
Mike EV; Makinde HM; Der E; Stock A; Gulinello M; Gadhvi GT; Winter DR; Cuda CM; Putterman C
Front Immunol; 2018; 9():2189. PubMed ID: 30319641
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
20. Investigating the Mitoprotective Effects of S1P Receptor Modulators Ex Vivo Using a Novel Semi-Automated Live Imaging Set-Up.
Ludwig R; Malla B; Höhrhan M; Infante-Duarte C; Anderhalten L
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
